Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 13;62(15):11. doi: 10.1167/iovs.62.15.11

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2021 The Authors

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

PMC Copyright notice

Figure 6. — PLK1 contributed to tumor progression. (a) RNA-sequence analysis was performed to evaluate the transcriptome of three retinoblastoma samples and normal retina samples. (b) The expression level of PLK1 in the retinoblastoma cells was verified by Western blot. (c) Efficiency of PLK1 knockdown in Y79 cells by siRNAs was verified by Western blot. (d) CCK8 assay showing tumor cell growth after PLK1 knockdown. Cell growth was restrained in PLK1 KD Y79 cells. The absorbance values were detected at 0, 24, 48, 72, and 96 hours, and the control was arbitrarily set at 100% on 0 hour. ****P < 0.0001. (e) siPLK1 Y79 cells were more prone to apoptosis. The percentage of apoptotic cells was analyzed by flow cytometry. Error bars represent the SD of three replicates. The P values were from two-way ANOVA, **P < 0.01, ***P < 0.001, and ****P < 0.0001. (f) Schematic model of xanthatin inhibiting retinoblastoma cell growth via the PLK1-mediated G2/M cell cycle pathway.